Online Articles: Clinical and Laboratory ObservationsBone Marrow Necrosis in a Patient Following Blinatumomab TherapyYarali, Nese MD*; Isik, Melek MD*; Arman-Bilir, Ozlem MD*; Guzelkucuk, Zeliha MD*; Oguz-Erdogan, Ayse Selcen MD†Author Information Departments of *Pediatric Hematology/Oncology †Pathology, University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, Turkey The authors declare no conflict of interest. Reprints: Nese Yarali, MD, Associate Professor, Department of Pediatric Hematology/Oncology, University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Şehit Ömer Halisdemir Caddesi, Kurtdereli Sok, 06110, Altindağ, Ankara, Turkey (e-mail: firstname.lastname@example.org). Received July 11, 2018 Accepted May 17, 2019 Journal of Pediatric Hematology/Oncology: April 2020 - Volume 42 - Issue 3 - p e167-e169 doi: 10.1097/MPH.0000000000001532 Buy Metrics Abstract Bone marrow necrosis (BMN) is an extremely rare condition characterized by necrosis of the myeloid tissue and medullary stroma leaving an amorphous eosinophilic background and ill-defined necrotic cells in the hematopoietic bone marrow. Several conditions are associated with BMN, including sickle cell disease, metastatic carcinoma, and hematologic malignancies. It is also associated with the use of antineoplastic drugs, such as fludarabine, interferon alpha, and imatinib. Blinatumomab is a CD19/CD3 bispecific T-cell engager antibody which redirects autologous CD3-positive T cells to CD19-positive lymphoblasts creating a cytolytic synapse leading to blastic cells. Cytokine release syndrome, cerebral nervous system toxicities, and febrile neutropenia are the most frequent adverse effects of blinatumomab. Here, we report an adolescent boy with relapse/resistant acute lymphoblastic leukemia developing BMN following blinatumomab therapy. To our knowledge, this is the first case report on BMN following blinatumomab treatment. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.